1 Migal

Schizophrenia Case Study Presentation Of Hypertension

Commercial Supporter

Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Conflicts of Interest

The Universtiy of Cincinnati ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, the University of Cincinnati identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by the University of Cincinnati to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The University of Cincinnati is committed to providing its learners with high quality CME activities that promote improvements or quality in health care and not the business interest of a commercial interest.


Henry A. Nasrallah, MD
Professor of Psychiatry & Neuroscience
Vice Chair/Education and Training
Director, Schizophrenia Program
University of Cincinnati College of Medicine
Cincinnati, OH

Henry A. Nasrallah, MD, serves on the advisory board for Boehringer Ingelheim, Genentech, Merck, Otsuka, and Sunovion. He is on the speakers’ bureau for Janssen, Merck, Novartis, Otsuka, and Sunovion. He also is a grant recipient for Novartis, Otsuka, Roche, and Shire.

Publishing and Planning Staff Disclosures

Susan Basilico, Eileen McCaffrey, and Krista Sierra of Haymarket Mecical Education, have no financial relationships to disclose with regard to commercial interest.

CME Accreditation - Susan P. Tyler, MEd, CMP, CCMEP, CME Director, University of Cincinnati, has nothing to disclose.

CME Reviewer - Rick Ricer, MD, University of Cincinnati, has nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. The University of Cincinnati, HME, and Janssen Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of The University of Cincinnati, HME or Janssen Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The planning committee, faculty, University of Cincinnati, HME, and Janssen Pharmaceuticals shall in no way be liable for the currency of information or any errors, omissions, or inaccuracies in the activity. The opinions and recommendations presented herein are those of the faculty and do not necessarily reflect the views of the provider, producer, or grantors. Participants are encouraged to refer to primary references of full prescribing information resources.


To obtain credit, a score of 70% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required

1. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med. 1991;324:746–54.[PubMed]

2. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull. 1991;17:247–61.[PubMed]

3. Gupta S, Rajaprabhakaran R. Paradoxical hypertension associated with clozapine. Am J Psychiatry. 1994;151:148.[PubMed]

4. George TP, Winther LC. Hypertension after initiation of clozapine. Am J Psychiatry. 1996;153:1368–9.[PubMed]

5. Ennis LM, Parker RM. Paradoxical hypertension associated with clozapine. Med J Aust. 1997;166:278.[PubMed]

6. Visscher AJ, Cohen D. Periorbital oedema and treatment-resistant hypertension as rare side effects of clozapine. Aust N Z J Psychiatry. 2011;45:1097–8.[PubMed]

7. Hoorn EJ, van der Poel MF. Hypokalemic hypertension related to clozapine: A case report. J Clin Psychopharmacol. 2014;34:390–2.[PubMed]

8. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D, et al. Clozapine and hypertension: A chart review of 82 patients. J Clin Psychiatry. 2004;65:686–9.[PubMed]

9. Josiassen R, Filmyer DM, Curtis J, Shaughnessy RA, Joseph A, Parson R, et al. An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients. Clin Schizophr Relat Psychoses. 2009;3:87–96.

10. Nebhinani N, Grover S, Chakrabarti S, Kate N, Avasthi A. A longitudinal study of change in prevalence of metabolic syndrome and metabolic disturbances 3 months after Clozapine therapy. J Ment Health Hum Behav. 2013;18:9–17.

11. Barry AR, Windram JD, Graham MM. Clozapine-associated myocarditis: Case report and literature review. Can J Hosp Pharm. 2015;68:427–9.[PMC free article][PubMed]

12. Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand. 2015;132:231–40.[PubMed]

13. Youssef DL, Narayanan P, Gill N. Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Australas Psychiatry. 2016;24:176–80.[PubMed]

14. Sara J, Jenkins M, Chohan T, Jolly K, Shepherd L, Gandhi NY, et al. Clozapine use presenting with pseudopheochromocytoma in a schizophrenic patient: A case report. Case Rep Endocrinol. 2013;2013:194927.[PMC free article][PubMed]

15. Krentz AJ, Mikhail S, Cantrell P, Hill GM. Drug points: Pseudophaeochromocytoma syndrome associated with clozapine. BMJ. 2001;322:1213.[PMC free article][PubMed]

16. Li JK, Yeung VT, Leung CM, Chow CC, Ko GT, So WY, et al. Clozapine: A mimicry of phaeochromocytoma. Aust N Z J Psychiatry. 1997;31:889–91.[PubMed]

17. Akinsola O, Ong K. Pseudophaeochromocytoma associated with clozapine therapy: A case report. Afr J Psychiatry (Johannesbg) 2011;14:406. 408. [PubMed]

18. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.[PubMed]

19. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: A claims-based approach. Arch Gen Psychiatry. 2001;58:1172–6.[PubMed]

20. Shiwach RS. Treatment of clozapine induced hypertension and possible mechanisms. Clin Neuropharmacol. 1998;21:139–40.[PubMed]

21. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH, et al. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry. 1992;49:345–53.[PubMed]

22. Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, et al. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res. 1993;46:151–63.[PubMed]

23. Walther MM, Keiser HR, Linehan WM. Pheochromocytoma: Evaluation, diagnosis, and treatment. World J Urol. 1999;17:35–9.[PubMed]

24. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.[PubMed]

Leave a Comment


Your email address will not be published. Required fields are marked *